Table 1:
Patient, Tumor, and Radiotherapy Characteristics* (n=100 patients/118 lesions)
| Characteristic | Number/Median (range) |
|---|---|
| Age (years) | 67 (44-91) |
| Sex | 59 female 41 male |
| Race | 42 African American 58 Caucasian |
| Smoking Status | 58 quit within 1 year 30 yes 12 no |
| Location of Tumor | 72 upper lobe 6 middle lobe 40 lower lobe |
| Diabetes | 18 yes 82 no |
| Karnofsky Performance Status (%) | 80 (50-100) |
| Body Mass Index | 27 (14.3-47) |
| Smoking (pack years) | 45 (0-240) |
| Bone Mineral Density (HU) | 149.7 (38-388) |
| Statin Use | 49 yes 51 no |
| Inhaled Corticosteroids | 55 yes 45 no |
| Systemic Steroids | 9 yes 91 no |
| ACEi Use | 34 yes 66 no |
| NSAID Use | 47 yes 53 no |
| Primary Tumor or Metastasis | 18 metastases 100 primary lesions |
| Biologically Effective Dose (BED) of Prescription (Gy, α/β=10 Gy) | 105.6 (48-151.2) |
| Equivalent Prescription Dose in 2Gy per Fraction (Gy, α/β=10 Gy) | 144 (54–226.8) |
| Planning Target Volume (PTV) (cc) | 23 (3.9-292) |
| Treatment Technique | 101 IMRT 17 VMAT |
| PTV-Chest Wall Distance (cm) | 0 (0-6) |
| V10Gy (cc) | 328.6 (30.2-820.5) |
| V20Gy (cc) | 72.8 (0-427.4) |
| V30Gy (cc) | 17.6 (0-266.1) |
| V40Gy (cc) | 4.9 (0-62.6) |
| CW Mean Dose (Gy) | 5.5 (2.72-34.2) |
| CW Max Dose (Gy) | 51.6 (19.9-103.2) |
| CW D30cc (Gy) | 26.3 (11.8-45.2) |
HU: Hounsfield units; cc: cubic centimeters; IMRT: Intensity Modulated Radiation Therapy; VMAT: Volumetric Modulated Arc Therapy; ACEi: Angiotensin converting enzyme inhibitor; NSAID: Non-steroidal anti-inflammatory drug; CW: Chest Wall
*
All except location, treatment technique, dosimetric data, PTV, BED and primary versus metastasis are based on patient number, not individual lesions.